Novo Nordisk (NOVOB.DK) is down more than 5.5% today following the release of Phase 3 clinical trial results for its new obesity drug, CagriSema. The company reported positive study outcomes, showing that patients with type 2 diabetes and obesity experienced a 15.7% reduction in body weight after 68 weeks of treatment, compared to a 3.1% weight loss in the placebo group. However, prior expectations (before the December 20 report) anticipated a 25% weight reduction.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appNovo Nordisk's stock is currently trading at this year’s support level around 550 DKK, a zone defined by the consolidation phase before the strong rally in 2023, driven by positive results from its Wegovy obesity drug. Source: xStation
The company stated that the study confirmed high drug efficacy, and it plans to submit the drug for regulatory approval in Q1 2026.
Despite the positive trial results, investors reacted with a significant sell-off. Today’s drop marks the biggest one-day decline since the December 20 selloff, which occurred after the company published initial CagriSema trial results. Earlier company expectations projected a 25% weight reduction, while December’s data suggested around 20% weight loss.
Another factor that may have disappointed investors is the proportion of patients opting for the maximum drug dose, which was approximately 61%. In this trial, patients had the option to self-adjust their dosage levels.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
